Substance / Medication

Larotrectinib sulfate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes.
Habiburrahman Muhammad, Flanagan James M · Crit Rev Oncol Hematol · 2026
PMID: 41223982Meta-Analysis
SLC7A11 as a molecular nexus of prognosis, resistance, and therapeutic roadmap in cancer: A systematic review and meta-analysis.
Sharma Arpana, Srivastava Yogesh, Prasad Sanway et al. · Int J Biol Macromol · 2026
PMID: 41308763Meta-Analysis
Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia.
Park Daniel, Chan-Golston Alec M, Yan Yueqi et al. · J Chemother · 2025
PMID: 38803142Meta-Analysis
p27and cytoplasmic pSer10p27 are promising biomarkers for predicting prognosis and chemotherapy response in ovarian cancer.
Zhu Mengna, Sun Si, Huang Lin et al. · Histol Histopathol · 2025
PMID: 38818655Meta-Analysis
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.
Tian Linyan, Liu Chengming, Zheng Sufei et al. · J Transl Med · 2025
PMID: 39825361Meta-AnalysisFull text (PMC)
Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review.
McKenna Matthew, Linganathan Saranya, Li Amber et al. · Histol Histopathol · 2025
PMID: 39916554Meta-Analysis
Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.
Karimi Mohammad Amin, Norooziseyedhosseini Hanieh, Khademi Reza et al. · BMC Pharmacol Toxicol · 2025
PMID: 40001241Meta-AnalysisFull text (PMC)
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.
Tan Chia Jie, Kacerek Dylan, Kampirapawong Nattawara et al. · Cancer Med · 2025
PMID: 40052837Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Larotrectinib sulfate (substance)
SNOMED CT
1217200005
UMLS CUI
C4740883

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.